专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0178767A3 PHARMACEUTICAL PREPARATIONS COMPRISING MODIFIED PEPTIDES 审中-公开
标题翻译：包含改性肽的药物制剂
公开(公告)号：WO0178767A3
公开(公告)日：2002-02-28
申请号：PCT/EP0104313
申请日：2001-04-17
申请人： CISTEM BIOTECHNOLOGIES GMBH , MATTNER FRANK , ZAUNER WOLFGANG , SCHMIDT WALTER , BUSCHLE MICHAEL
发明人： MATTNER FRANK , ZAUNER WOLFGANG , SCHMIDT WALTER , BUSCHLE MICHAEL
IPC分类号： A61K38/00 , A61K39/00 , A61K39/385 , A61P31/04 , A61P37/00 , A61P37/02 , A61P37/04 , C07K7/04 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/77
CPC分类号： C07K7/06 , A61K39/385 , A61K2039/55561 , A61K2039/6031 , A61K2039/64 , C07K7/08 , C07K14/001 , C07K14/77
摘要： Pharmaceutical preparation comprising a peptide of the formula : X>N L M L N M L
摘要翻译：药物制剂，其包含下式的肽：X> N < - 肽> L <-X> M < 其中X是选自Gly，Ala，Val，Leu，Ile，Pro，Phe，Tyr，Trp，Cys，Met，Glu和Asp的氨基酸残基; 肽> L <是由L氨基酸残基组成的潜在免疫原性片段; L是6至100的整数，N和M是0-2L的整数，条件是N或M至少为2; X> N <和X> M是不存在于该位置的氨基酸序列，并且在该星座中具有肽> L <和聚阳离子物质。

2. 发明申请

WO0232451A8 VACCINE COMPOSITION COMPRISING AN ANTIGEN AND A PEPTIDE HAVING ADJUVANT PROPERTIES 审中-公开
标题翻译：包含抗原和具有佐剂特性的肽的疫苗组合物
公开(公告)号：WO0232451A8
公开(公告)日：2002-05-23
申请号：PCT/EP0112041
申请日：2001-10-18
申请人： CISTEM BIOTECHNOLOGIES GMBH , FRITZ JOERG , MATTNER FRANK , ZAUNER WOLFGANG , NAGY ESZTER , BUSCHLE MICHAEL
发明人： FRITZ JOERG , MATTNER FRANK , ZAUNER WOLFGANG , NAGY ESZTER , BUSCHLE MICHAEL
IPC分类号： A61K38/00 , A61K39/00 , A61K39/39 , A61P37/04
CPC分类号： C07K7/06 , A61K39/0011 , A61K39/39 , A61K2039/55516
摘要： The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1-XZXZNXZX-R2, whereby N is a whole number between 3 and 7, preferably 5, -X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independently are from the other from the group consisting of -H, -NH2, -COCH3, -COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X-R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
摘要翻译：本发明涉及包含至少一种抗原和包含序列R1-XZXZNXZX-R2的肽的疫苗，其中N是3至7，优选5的整数，-X是带正电的天然和/ 天然氨基酸残基，Z是选自L，V，I，F和/或W的氨基酸残基，并且R 1和R 2独立地选自由以下组成的组：-H，-NH 2 ，-COCH 3，-COH，具有至多20个氨基酸残基的肽或肽反应性基团或具有或不具有肽的肽接头; X-R2也可以是C-末端氨基酸残基的酰胺，酯或硫酯，以及所述肽用于制备佐剂以增强对至少一种抗原的免疫应答的用途。

3. 发明申请

WO02053184A3 USES FOR POLYCATIONIC COMPOUNDS AS VACCINE ADJUVANTS 审中-公开
标题翻译：用作聚合化合物作为疫苗辅助剂
公开(公告)号：WO02053184A3
公开(公告)日：2002-09-19
申请号：PCT/EP0200062
申请日：2002-01-07
申请人： INTERCELL BIOMEDIZINISCHE FORSCHUNGS & ENTWICKLUNGS GMBH , CISTEM BIOTECHNOLOGIES GMBH , LINGNAU KAREN , MATTNER FRANK , SCHMIDT WALTER , BIRNSTIEL MAX , BUSCHLE MICHAEL
发明人： LINGNAU KAREN , MATTNER FRANK , SCHMIDT WALTER , BIRNSTIEL MAX , BUSCHLE MICHAEL
IPC分类号： A61K39/00 , A61K39/02 , A61K39/12 , A61K39/39 , A61K47/48 , A61P35/00 , A61P37/00 , A61K31/7084 , A61K31/7125 , A61K39/002
CPC分类号： A61K39/39 , A61K39/00 , A61K47/645 , A61K2039/55516 , A61K2039/55561 , A61K2039/55572
摘要： The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.
摘要翻译：本发明涉及聚阳离子化合物用于制备具有延缓体内释放的药物的用途。

4. 发明申请

WO0124822A3 PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIGEN 审中-公开
标题翻译：包含抗原的药物组合物
公开(公告)号：WO0124822A3
公开(公告)日：2001-12-20
申请号：PCT/EP0009657
申请日：2000-10-02
申请人： CISTEM BIOTECHNOLOGIES GMBH , FLEITMANN JULIA KRISTINA , MATTNER FRANK , BUSCHLE MICHAEL , MELLING JACK
发明人： FLEITMANN JULIA-KRISTINA , MATTNER FRANK , BUSCHLE MICHAEL , MELLING JACK
IPC分类号： A61K39/39 , A61P37/04 , C07K14/18 , A61K39/29 , A61P31/00 , A61P35/00 , A61P37/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K39/39 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55555 , A61K2039/55583 , C12N2710/16234 , C12N2740/16034 , C12N2770/24222 , C12N2770/24234
摘要： The inventions discloses a pharmaceutical composition comprising an antigen, an immunostimulating substance selected from neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.
摘要翻译：本发明公开了一种药物组合物，其包含抗原，选自神经活性化合物，激素，具有生长激素活性的化合物及其混合物的免疫刺激物质和聚阳离子聚合物。

5. 发明申请

WO0213857A3 A VACCINE WHICH COMPRISES AT LEAST ONE ANTIGEN AND A CATHELIDIDIN DERIVED ANTIMICROBIAL PEPTIDE OR A DERIVATIVE THEREOF 审中-公开
标题翻译：包含至少一种抗原的疫苗和衍生自蒽环类抗微生物肽或其衍生物的疫苗
公开(公告)号：WO0213857A3
公开(公告)日：2002-07-11
申请号：PCT/EP0109529
申请日：2001-08-17
申请人： CISTEM BIOTECHOLOGIES GMBH , FRITZ JOERG , MATTNER FRANK , ZAUNER WOLFGANG , BUSCHLE MICHAEL , EGYED ALENA
发明人： FRITZ JOERG , MATTNER FRANK , ZAUNER WOLFGANG , BUSCHLE MICHAEL , EGYED ALENA
IPC分类号： A61K39/385 , A61K39/39 , A61P37/04
CPC分类号： A61K39/385 , A61K39/39 , A61K2039/55516 , A61K2039/6031
摘要： Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
摘要翻译：描述了包含至少一种抗原和至少一种导管素衍生的抗微生物肽或其衍生物的疫苗，以及导管素衍生的抗微生物肽或其衍生物在制备佐剂中的用途，所述佐剂用于增强对至少一种抗原。

6. 发明申请

WO0213857A8 A VACCINE WHICH COMPRISES AT LEAST ONE ANTIGEN AND A CATHELIDIDIN DERIVED ANTIMICROBIAL PEPTIDE OR A DERIVATIVE THEREOF 审中-公开
公开(公告)号：WO0213857A8
公开(公告)日：2002-05-10
申请号：PCT/EP0109529
申请日：2001-08-17
申请人： CISTEM BIOTECHOLOGIES GMBH , FRITZ JOERG , MATTNER FRANK , ZAUNER WOLFGANG , BUSCHLE MICHAEL , EGYED ALENA
发明人： FRITZ JOERG , MATTNER FRANK , ZAUNER WOLFGANG , BUSCHLE MICHAEL , EGYED ALENA
IPC分类号： A61K39/385 , A61K39/39 , A61P37/04
CPC分类号： A61K39/385 , A61K39/39 , A61K2039/55516 , A61K2039/6031
摘要： Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

7. 发明申请

WO2004024182A3 METHOD FOR ISOLATING HEPATITIS C VIRUS PEPTIDES 审中-公开
标题翻译：用于分离HEPATITIS C病毒肽的方法
公开(公告)号：WO2004024182A3
公开(公告)日：2004-12-23
申请号：PCT/EP0309482
申请日：2003-08-27
申请人： INTERCELL AG , BUSCHLE MICHAEL , HABEL ANDRE , KLADE CHRISTOPH , MATTNER FRANK , OTAVA OLEKSANDR , VYTVYTSKA ORESTA , ZAUNER WOLFGANG , ZINKE SANDRA , KIRLAPPOS HELEN
发明人： BUSCHLE MICHAEL , HABEL ANDRE , KLADE CHRISTOPH , MATTNER FRANK , OTAVA OLEKSANDR , VYTVYTSKA ORESTA , ZAUNER WOLFGANG , ZINKE SANDRA , KIRLAPPOS HELEN
IPC分类号： A61K38/00 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/29 , C07K7/06 , C07K7/08 , C07K14/005 , C07K14/045 , C07K14/11 , C07K14/18 , G01N33/576 , A61K38/04 , A61K38/16 , C07K7/04 , G01N33/50 , G01N33/569
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/292 , A61K2039/525 , A61K2039/57 , C07K7/08 , C07K14/005 , C07K2319/00 , C12N2710/16122 , C12N2760/16122 , C12N2770/24222 , C12N2770/24234 , G01N2500/04 , Y10S930/223
摘要： Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: - providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, -contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, -detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterising the HCV-peptide from said complex.
摘要翻译：描述了一种分离具有与MHC / HLA分子的结合能力的丙型肝炎病毒肽（HP）的方法或包含所述HCV-肽和所述MHC / HLA分子的复合物的方法，其特征在于以下步骤： - 提供HCV池肽，所述池包含结合所述MHC / HLA分子的HCV-肽和不结合所述MHC / HLA分子的HCV-肽， - 用所述HCV-肽池接触所述MHC / HLA分子，由此HCV- 具有与所述MHC / HLA分子的结合能力的肽与所述MHC / HLA分子结合，形成包含所述HCV-肽和所述MHC / HLA分子的复合物，检测并任选地从所述HCV-肽分离所述复合物不结合所述MHC / HLA分子，并且任选地从所述复合物中分离和表征HCV-肽。

8. 发明申请

WO03073097A9 METHOD FOR ISOLATING LIGANDS 审中-公开
标题翻译：分离配体的方法
公开(公告)号：WO03073097A9
公开(公告)日：2003-12-24
申请号：PCT/EP0302005
申请日：2003-02-27
申请人： INTERCELL AG , KLADE CHRISTOPH , SCHALICH JULIANE , VYTVYTSKA ORESTA , ZAUNER WOLFGANG , BIRNSTIEL MAX , AICHINGER GERALD , OTAVA ALEXANDER , MATTNER FRANK
发明人： KLADE CHRISTOPH , SCHALICH JULIANE , VYTVYTSKA ORESTA , ZAUNER WOLFGANG , BIRNSTIEL MAX , AICHINGER GERALD , OTAVA ALEXANDER , MATTNER FRANK
IPC分类号： C12Q1/02 , A61K35/12 , A61K38/00 , A61K39/245 , A61P31/12 , A61P43/00 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/045 , G01N33/50 , A61K39/00 , C07K14/705 , C12N5/06
CPC分类号： C07K7/06 , A61K2039/57 , C07K7/08 , C07K14/005 , C12N2710/16122 , G01N2500/04
摘要： Described is a method for isolating ligands which have a binding capacity to a MHC/HLA molecule or a complex comprising said ligand and said MHC/HLA molecule which method comprises the following steps: - providing a pool of ligands, said pool containing ligands which bind to said MHC/HLA molecule and ligands which do not bind to said MHC/HLA molecule, - contacting said MHC/HLA molecule with said pool of ligands whereby a ligand which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said ligand and said MHC/HLA molecule is formed, - detecting and optionally separating said complex from the ligands which do not bind to said MHC/HLA molecule and - optionally isolating and characterising the ligand from said complex as well as a method for isolating T cell epitopes which have a binding capacity to a MHC/HLA molecule.
摘要翻译：描述了用于分离对MHC / HLA分子或包含所述配体和所述MHC / HLA分子的复合物具有结合能力的配体的方法，所述方法包括以下步骤： - 提供配体库，所述库含有结合配体对所述MHC / HLA分子和不与所述MHC / HLA分子结合的配体， - 使所述MHC / HLA分子与所述配体库接触，由此具有与所述MHC / HLA分子结合能力的配体与所述MHC / HLA分子和包含所述配体和所述MHC / HLA分子的复合物， - 检测并任选地将所述复合物从不与所述MHC / HLA分子结合的配体分离，以及 - 任选地从所述复合物分离和表征配体作为分离对MHC / HLA分子具有结合能力的T细胞表位的方法。

9. 发明申请

WO2009149487A3 COMPOUNDS FOR TREATING SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE 审中-公开
标题翻译：用于治疗与帕金森病相关的症状的化合物
公开(公告)号：WO2009149487A3
公开(公告)日：2010-07-29
申请号：PCT/AT2009000237
申请日：2009-06-12
申请人： AFFIRIS AG , MANDLER MARKUS , MATTNER FRANK , SCHMIDT WALTER
发明人： MANDLER MARKUS , MATTNER FRANK , SCHMIDT WALTER
IPC分类号： A61K38/08 , A61P25/16 , A61P25/28 , C07K16/18
CPC分类号： A61K39/00 , A61K38/08 , C07K7/06 , C07K16/18 , C07K2317/34
摘要： The present invention relates to a compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (Aß).
摘要翻译：本发明涉及包含用于治疗，预防和/或改善帕金森病运动症状的肽的化合物，所述肽具有对淀粉样蛋白-β-肽（Aß）的表位特异的抗体的结合能力。

10. 发明申请

WO2006005707A2 METHOD FOR PREVENTING AND TREATING ALZHEIMER´S DISEASE 审中-公开
标题翻译：预防和治疗阿尔茨海默病的方法
公开(公告)号：WO2006005707A2
公开(公告)日：2006-01-19
申请号：PCT/EP2005053225
申请日：2005-07-06
申请人： MATTNER FRANK , SCHMIDT WALTER
发明人： MATTNER FRANK , SCHMIDT WALTER
IPC分类号： A61K39/00 , A61K38/08 , A61P25/28 , G01N33/68
CPC分类号： G01N33/6896 , A61K39/0007 , G01N2800/2821
摘要： The invention relates to the use of a compound comprising the following amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 , wherein X1 is an amino acid, except of C, X 2 is an amino acid, except of C, X 3 is an amino acid, except of C, X 4 is an amino acid, except of C, X 5 is an amino acid, except of C, X 6 is not present or any amino acid, X 7 is not present or any amino acid, and wherein X 1 X 2 X 3 X 4 X 5 X 6 is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal Aß42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal Aß42 sequence DAEFRH, for the preparation of a vac- cine for Alzheimer's disease.
摘要翻译：本发明涉及包含以下氨基酸序列X 1，X 2，X 3，X 4，N 2的化合物的用途其中X 1是除C以外的氨基酸，X 2是（C 1 -C 6）除了C，X 3 N以外的氨基酸是氨基酸，除了C以外，X 4是氨基酸，除了C，X 5， / SUB>是除C以外的氨基酸，不存在X 6或不存在任何氨基酸，X 7不存在或任何氨基酸，并且其中X < SUB> 1 X _{2 X _{3 X _{4 X _{5 X _{6 不是DAEFRH，所述化合物具有对天然N端Aβ42序列DAEFRH特异性的抗体的结合能力，并且具有对所述抗体的结合能力的5聚体对于天然N-末端Aβ42序列DAEFRH是特异性的，用于制备阿尔茨海默病疫苗。}}}}}

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式